Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026
Basics
Sector
Basic Materials
Industry
Specialty Chemicals
Country
United States
Market cap
2.5B USD
Enterprise value
3.5B USD
Full-time employees
1,400
Overall health
Strength:more profitable than most peersmore profitable than peers
Strength:its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 1.14 vs a peer median of 0.69) and more debt relative to equity (25.59× vs a peer median of 0.36×)higher risk: bigger price swings (beta 1.14 vs peers 0.69) and more debt vs equity (25.59× vs peers 0.36×)
Ranks #405 of 1,217 basic materials companies (top 34%)
Much more borrowing than peers.Debt is 25.6× equity vs a peer median of 0.4×.Debt is 25.6× equity vs peers 0.4×.
Debt is 25.6× shareholders' equity, against a peer median of 0.4×, among the highest 10% of its peer group.Debt is 25.6× shareholders' equity, vs peers 0.4×, among the highest 10% of its peer group.
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Ingevity made a profit per share in its latest year after a loss the year before.
Annual revenue fell three years running. Fiscal-year revenue down each year from 2022 to 2025.
Ingevity's fiscal-year revenue declined in each of the three years to 2025.
Share count shrinking. Shares outstanding down 7.8% from December 2022 to July 2026.
Ingevity had 7.8% fewer shares at July 2026 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Ingevity
Is Ingevity getting weaker?
Its latest SEC filing (Jul 30, 2026) got stronger: turned profitable over the last 12 months; net margin rose 15.5 points to 4.7%. Its overall score is unchanged at 60/100 since Oct 28, 2026.
How is Ingevity valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 67/100 against 1,371 basic materials peers.EBITDA yield 14.3% vs a peer median of 8.5% (stronger than 78% of peers).EBITDA yield 14.3% vs peers 8.5% (stronger than 78% of peers).
Is Ingevity growing?
Yes, faster than most of its peers. Growth scores 78/100 against 1,371 basic materials peers.Revenue growth 10.6% vs a peer median of 3.4% (stronger than 69% of peers).Revenue growth 10.6% vs peers 3.4% (stronger than 69% of peers).3-year revenue growth -12.6% vs a peer median of -0.0% (weaker than 88% of peers).3-year revenue growth -12.6% vs peers -0.0% (weaker than 88% of peers).
How profitable is Ingevity?
More profitable than most of its peers. Profitability scores 90/100 against 1,371 basic materials peers.Operating margin 36.1% vs a peer median of 7.6% (stronger than 93% of peers).Operating margin 36.1% vs peers 7.6% (stronger than 93% of peers).
How risky is Ingevity?
Higher risk relative to 1,371 basic materials peers, judged on debt, liquidity and share-price swings.Debt / equity 25.59× vs a peer median of 0.36× (weaker than 100% of peers).Debt / equity 25.59× vs peers 0.36× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Mar 31, 2026
Got stronger
Turned profitable over the last 12 months
Net margin rose 15.5 points to 4.7%
Previous quarter
Latest quarter
Change
Revenue (12 months)
1.2B USD
1.2B USD
−1.5%
Net income (12 months)
−127.8M USD
54.0M USD
turned positive
Free cash flow (12 months)
245.8M USD
154.9M USD
−37.0%
Debt
1.2B USD
1.2B USD
−0.3%
Cash
95.4M USD
97.4M USD
+2.1%
Shares outstanding
34.8M
34.4M
−1.1%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Industry: Specialty Chemicals · 32 companies
Valuations in Specialty Chemicals are above their usual range since 2016.
74% of months since 2016 were valued lower than now.
17% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +13% (medians): earnings grew faster than prices.
Median price-to-sales is −36% vs the whole market, against a usual −31%.
2016Shaded: most expensive fifth of its range2026
This is a cyclical group: after a downturn, trailing earnings and sales fall faster than prices, which can make valuations look high near a cycle's low.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on earnings, EBITDA, sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
36.9%
34.2%
36.6%
38.7%
39.5%
▲ 0.8 pts
Operating margin
30.3%
27.1%
34.8%
35.5%
35.9%
▲ 0.4 pts
Net margin
8.5%
12.7%
-0.4%
-35.9%
-14.3%
▲ 22 pts
Return on assets (ROA)
4.8%
7.7%
-0.2%
-21.3%
-10.1%
▲ 11 pts
Return on equity (ROE)
17.5%
30.3%
-0.9%
-220.4%
—
—
Free cash flow margin
13.6%
10.2%
7.8%
4.2%
23.4%
▲ 19 pts
Current ratio
2.70×
2.25×
1.81×
1.87×
1.33×
▼ 29%
Quick ratio
1.80×
1.15×
0.96×
1.13×
0.79×
▼ 30%
Debt to equity
1.88×
2.11×
2.32×
7.18×
—
—
Interest coverage
8.17×
7.32×
4.54×
4.35×
5.35×
▲ 23%
NGVT price history
Price history is added with the daily price update and will appear after the next one.